Recce has opted to carry out its phase III diabetic foot injury trial in Indonesia – which looks a safer ... Read More The ...

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was ...

The Recce commandos not only faced the terrorist head-on, leaving them no chance, but strived to ensure all survivors were evacuated safely and as fast as possible. Most of the members had key ...

A Phase II trial of Recce Pharmaceutical’s topical skin infection gel has ‘exceeded expectations’, with 93% of patients achieving the primary efficacy endpoint. The Australian company’s ...

RECCE 327 developed by Recce Pharmaceuticals Ltd (ASX:RCE) has destroyed every bacterium it has been tested against, including superbugs, and has proved invulnerable to any attempt by bacteria to ...

Security agencies have assured the public that there was no immediate threat and that measures remain in place to safeguard ...

There's more to work than life.

Recce awarded expedited regulatory review status in Indonesia to fast-track progression of trial Company on track to start trial this quarter Special Report: Recce Pharmaceuticals has received ...

Recce Pharmaceuticals SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti ...